Fact-Check Article: "Does GS1 Really Make Someone Lose Weight?"
What We Know
The claim that "GS1 really makes someone lose weight" appears to be a misunderstanding or misrepresentation of the role of GLP-1 receptor agonists (GLP-1 RAs), which are sometimes referred to in discussions about weight loss. According to a 2023 study published in the Journal of Clinical Endocrinology & Metabolism, GLP-1 agonists have been shown to result in modest weight loss among patients with type 2 diabetes. The study found that patients experienced a mean weight loss of 2.2% after 72 weeks of treatment, with one-third of patients losing at least 5% of their body weight.
Moreover, a narrative review from 2022 highlights that GLP-1 RAs, such as liraglutide and semaglutide, have been approved for chronic weight management and can lead to weight loss ranging from 4% to 6.2% in patients with diabetes, and even higher in those without diabetes, with some studies showing weight loss differences as high as 17.4% (Jensterle et al., 2022).
However, it is important to note that these medications are not a standalone solution for weight loss; they are typically prescribed alongside lifestyle interventions, such as diet and exercise, to enhance their effectiveness.
Analysis
The evidence surrounding GLP-1 receptor agonists indicates that while they can contribute to weight loss, the effectiveness varies based on individual circumstances, including the presence of diabetes. The studies referenced provide a clear picture of the potential for weight loss associated with GLP-1 agonists, but they also emphasize that the weight loss is often modest and not guaranteed for every individual.
The credibility of the sources is generally high, as they are published in peer-reviewed journals and conducted by reputable researchers in the field of endocrinology. For instance, the 2023 study from the University of Pittsburgh utilized a large cohort of over 2,400 patients and employed robust statistical methods to analyze the data, lending credibility to its findings (White et al., 2023).
Conversely, claims about GS1 (which may refer to a specific product or supplement claiming to enhance GLP-1 levels) are less substantiated. A recent article from NBC News warns that supplements marketed to boost GLP-1 levels are likely ineffective for weight loss (NBC News, 2025). This suggests that while GLP-1 agonists can aid in weight management, products claiming to enhance GLP-1 through supplementation should be approached with skepticism.
Conclusion
The claim that "GS1 really makes someone lose weight" is False. While GLP-1 receptor agonists can facilitate weight loss, particularly in individuals with type 2 diabetes, the weight loss is generally modest and depends on various factors, including adherence to lifestyle changes. Moreover, the notion that a specific product or supplement (referred to as GS1) can independently cause weight loss lacks sufficient scientific backing and should be regarded with caution.
Sources
- Real-world weight loss effectiveness of GLP-1 agonists among patients with type 2 diabetes: a retrospective cohort study
- Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review
- Real-world weight-loss effectiveness of glucagon-like peptide
- Research shows GLP-1 drugs are effective but complex
- Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
- Diabetes drugs and weight loss
- What to know about GLP-1 supplements for weight loss
- Rx Trends: Real-World Data on GLP-1s for Weight Loss
